奎硫平与利培酮治疗首发精神分裂症的对照研究

目的 :比较奎硫平与利培酮治疗首发精神分裂症的疗效和安全性。 方法 :将 60例首发精神分裂症患者随机分为奎硫平组 (3 0例 )和利培酮组 (3 0例 ) ,奎硫平组剂量范围 2 5～ 80 0mg/d ,利培酮组剂量范围 0 .5～ 6mg/d ,疗程 8周。用阳性和阴性症状量表 (PANSS)评定临床疗效 ,用副反应量表 (TESS)评定药物不良反应。 结果 :奎硫平治疗首发精神分裂症的有效率为 66.7% ,利培酮的有效率为 70 % ,两药的疗效无显著性差异。奎硫平组的不良反应较利培酮组少 ,其中震颤、静坐不能、肌强直等EPS的发生率显著少于利培酮组 (P <0 .0 1)。未出现月经失调 (闭经、经期过长或过短 ) ,泌乳、男性乳房发育、性欲减退、勃起障碍等副作用。 结论 :奎硫平与利培酮治疗首发精神分裂症的疗效相当 ,某些不良反应较利培酮轻而少 ,尤其适用对锥体反应和催乳素敏感患者使用。是一种有效、耐受性好的抗精神病药物

A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia

Objective: To compare efficacy and safety of domestic quetiapine and risperidone in the treatment of schizophrenia. Methods: Patients who met CCMD-3 criteria for schizophrenia were randomized in two groups: quetiapine group (n=30) and risperidone group (n=30). The range of dosage for the quetiapine group was 25~800mg/d, the range of dosage for the risperidone group was 0.5~0.6mg/d, the treatment duration was 8 weeks. The PANSS, TESS and related lab tests were employed for assessing the treatment effectiveness and side effects. Results: At the end of treatment, total clinical effective rates were 66.7% in quetiapine group and 70.0% in risperidone group, which was no significant difference between two groups. However, patients in quetiapine group reported much fewer side effects than those in risperidone group, especially in the EPS. In quetiapine group menstruation disorder (amenorrhea, prolonging or shortening of menstrual period), lactation, male's mammo-development, lack of sexuality and erective dysfunction did not appear. Conclusions: Domestic quetiapine has similar efficacy to risperidone, but has less side effects. It is suitable to the patients who are sensitive to the EPS and PRL particularly.